GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

etigilimab   Click here for help

GtoPdb Ligand ID: 13984

Synonyms: OMP-313M32
Immunopharmacology Ligand
Compound class: Antibody
Comment: Etigilimab (OMP-313M32) is an anti-TIGIT monoclonal antibody [1]. Blocking the TIGIT/PVR interaction is proposed to promote anti-tumour immunity. This mechanism is proposed to be used in conjunction with anti-PD/1/PD-L1 immuno-oncology therapeutics, to further enhance the anti-tumour immune response.
No information available.
Summary of Clinical Use Click here for help
Etigilimab (OMP-313M32) was trialled in combination with the anti-PD-1 immune checkpoint inhibitor nivolumab [1]. This led to initiation of a phase 2 trial in patients with advanced, platinum therapy-resistant ovarian cancer. It is unclear if development of etigilimab is ongoing.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03119428 A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1 Interventional Mereo BioPharma 1
NCT05715216 EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer Phase 2 Interventional M.D. Anderson Cancer Center